European Ophthalmic Drug Delivery Devices Market to Grow 6.4% by 2031 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–Added Europe Ophthalmic Drug Delivery System Market 2021-2031 by Product, Dosage Form, Disease, Setting, and Country: Trend Forecast and Growth Opportunity report ResearchAndMarkets.com Offer.

The European ophthalmic drug delivery system market was valued at US$3,856.3 million in 2021 and is expected to grow at an annual rate of 6.4% over the period 2021-2031, reflecting the increasing prevalence of eye diseases, the emerging novel ocular drug delivery systems and the rising Number of required ophthalmic procedures is attributed to attentive post-procedure care and the increasing demand for controlled dosage forms for the pediatric and geriatric populations.

In-depth qualitative analyzes include the identification and investigation of the following aspects:

• market structure

• growth accelerator

• limitations and challenges

• New product trends and market opportunities

• Porter’s Powers of Five

Based on Product, Europe market is segmented into the following sub-markets with Annual Revenue (Million USD) for 2021-2031 included in each segment.

• pre-filled syringes

• Multi-dose eye drops

• squeeze dispenser

• mist sprayer

• contact lenses

• eye inserts

• intraocular implants

• Punctual plugs

• Other products

Based on Dosage Form, Europe market is segmented into the following sub-markets with Annual Revenue (Million USD) for 2021-2031 included in each segment.

• solutions

• gels

• Anoint

• suspensions

• emulsions

• Liposomes & Nanoparticles

By Disease, Europe market is segmented into the following sub-markets with Annual Revenue (Million USD) for 2021-2031 included in each section.

• glaucoma

• Diabetic retinopathy

• cataract

• Dry Eye Syndrome

• macular degeneration

• Diabetic macular edema

• refraction problems

• Other diseases

Upon recruitment, the European market is segmented into the following sub-markets, with annual sales (USD million) for 2021-2031 included in each section.

• hospitals

• clinics

• Homecare Settings

• Ambulatory Surgery Centers (ASCs)

• Other options

Geographically, the following national/local markets are fully explored:

• Germany

• United Kingdom

• France

• Spain

• Italy

• Netherlands

• Rest of Europe (further subdivided into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark and Finland)

Selected key players

• Aeropump GmbH

• Allergan plc.

• AptarGroup, Inc.

• Becton, Dickinson and Company

• Biocorp

• Clearside Biomedical, Inc.

• EyePoint Pharmaceuticals, Inc.

• Gaplast Ltd

• Gerresheimer AG

• Jotteq Inc.

• Kedalion Therapeutics, Inc.

• Mati Therapeutics, Inc.

• Nemera

• Nipro Corporation

• Ocular Therapeutix, Inc.

• Ocumedic, Inc.

• Owen Muford

• Re-Vana Therapeutics

• Silgan Holdings Inc.

• Terumo Corporation

• Valeant Pharmaceuticals International Inc. (Bausch Health Company)

• West Pharmaceutical Services, Inc.

Main topics covered:

1 Introduction

2 Market overview and dynamics

3 European market segmentation by product

4 European market segmentation by dosage form

5 Segmentation of the European market by diseases

6 Segmentation of the European market by recruitment

7 European market 2021-2031 by country

8 competitive landscape

companies mentioned

• Aeropump GmbH

• Allergan plc.

• AptarGroup, Inc.

• Becton, Dickinson and Company

• Biocorp

• Clearside Biomedical, Inc.

• EyePoint Pharmaceuticals, Inc.

• Gaplast Ltd

• Gerresheimer AG

• Jotteq Inc.

• Kedalion Therapeutics, Inc.

• Mati Therapeutics, Inc.

• Nemera

• Nipro Corporation

• Ocular Therapeutix, Inc.

• Ocumedic, Inc.

• Owen Muford

• Re-Vana Therapeutics

• Silgan Holdings Inc.

• Terumo Corporation

• Valeant Pharmaceuticals International Inc. (Bausch Health Company)

• West Pharmaceutical Services, Inc.

For more information about this report, visit https://www.researchandmarkets.com/r/gaagf0